vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and Belpointe PREP, LLC (OZ). Click either name above to swap in a different company.
Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $3.1M, roughly 1.3× Belpointe PREP, LLC). On growth, Belpointe PREP, LLC posted the faster year-over-year revenue change (180.1% vs -10.2%). Over the past eight quarters, Belpointe PREP, LLC's revenue compounded faster (201.5% CAGR vs 50.3%).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
IRD vs OZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $3.1M |
| Net Profit | — | $-11.7M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | -380.8% |
| Revenue YoY | -10.2% | 180.1% |
| Net Profit YoY | 53.0% | -41.8% |
| EPS (diluted) | — | $-3.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $3.1M | ||
| Q3 25 | $3.1M | $2.4M | ||
| Q2 25 | $2.9M | $2.0M | ||
| Q1 25 | $4.4M | $1.7M | ||
| Q4 24 | $4.3M | $1.1M | ||
| Q3 24 | $3.9M | $860.0K | ||
| Q2 24 | $1.1M | $384.0K | ||
| Q1 24 | $1.7M | $337.0K |
| Q4 25 | — | $-11.7M | ||
| Q3 25 | $-17.5M | $-12.1M | ||
| Q2 25 | $-7.4M | $-7.6M | ||
| Q1 25 | $-8.2M | $-8.6M | ||
| Q4 24 | — | $-8.2M | ||
| Q3 24 | $-7.5M | $-6.9M | ||
| Q2 24 | $-7.8M | $-4.7M | ||
| Q1 24 | $-7.1M | $-4.0M |
| Q4 25 | — | — | ||
| Q3 25 | -269.9% | — | ||
| Q2 25 | -309.0% | — | ||
| Q1 25 | -227.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -207.1% | — | ||
| Q2 24 | -748.9% | — | ||
| Q1 24 | -450.5% | — |
| Q4 25 | — | -380.8% | ||
| Q3 25 | -566.9% | -509.3% | ||
| Q2 25 | -257.5% | -381.0% | ||
| Q1 25 | -187.5% | -495.6% | ||
| Q4 24 | — | -752.0% | ||
| Q3 24 | -194.6% | -805.6% | ||
| Q2 24 | -698.3% | -1229.2% | ||
| Q1 24 | -415.3% | -1181.3% |
| Q4 25 | — | $-3.10 | ||
| Q3 25 | $-0.25 | $-3.21 | ||
| Q2 25 | $-0.12 | $-2.06 | ||
| Q1 25 | $-0.24 | $-2.35 | ||
| Q4 24 | — | $-2.26 | ||
| Q3 24 | $-0.29 | $-1.90 | ||
| Q2 24 | $-0.30 | $-1.30 | ||
| Q1 24 | $-0.29 | $-1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $24.3M |
| Total DebtLower is stronger | — | $260.6M |
| Stockholders' EquityBook value | $15.3M | — |
| Total Assets | $50.2M | $564.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $24.3M | ||
| Q3 25 | $30.8M | $29.6M | ||
| Q2 25 | $32.4M | $25.0M | ||
| Q1 25 | $41.8M | $23.0M | ||
| Q4 24 | $30.3M | $24.7M | ||
| Q3 24 | $36.6M | $24.0M | ||
| Q2 24 | $41.4M | $24.7M | ||
| Q1 24 | $47.2M | $29.2M |
| Q4 25 | — | $260.6M | ||
| Q3 25 | — | $251.4M | ||
| Q2 25 | — | $228.4M | ||
| Q1 25 | — | $203.3M | ||
| Q4 24 | — | $177.0M | ||
| Q3 24 | — | $144.1M | ||
| Q2 24 | — | $119.9M | ||
| Q1 24 | — | $86.9M |
| Q4 25 | $15.3M | — | ||
| Q3 25 | $6.0M | — | ||
| Q2 25 | $17.5M | — | ||
| Q1 25 | $5.1M | — | ||
| Q4 24 | $6.7M | — | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | $40.6M | — | ||
| Q1 24 | $46.1M | — |
| Q4 25 | $50.2M | $564.2M | ||
| Q3 25 | $36.1M | $570.8M | ||
| Q2 25 | $38.7M | $556.8M | ||
| Q1 25 | $48.2M | $537.4M | ||
| Q4 24 | $36.9M | $517.6M | ||
| Q3 24 | $40.4M | $495.7M | ||
| Q2 24 | $44.8M | $476.2M | ||
| Q1 24 | $51.8M | $450.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-25.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-25.2M | ||
| Q3 25 | $-6.2M | $-6.0M | ||
| Q2 25 | $-10.3M | $-2.4M | ||
| Q1 25 | $-9.0M | $-6.6M | ||
| Q4 24 | $-25.6M | $-13.7M | ||
| Q3 24 | $-5.1M | $-3.3M | ||
| Q2 24 | $-7.3M | $1.2M | ||
| Q1 24 | $-5.7M | $-6.6M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
